Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference, scheduled for February 5-6, 2025, in New York. The company's CEO, Yuval Cohen, Ph.D., will engage in a fireside chat discussion led by analysts and conduct one-on-one meetings with investors.
The presentation is set for February 5, 2025, at 2:30 PM. The format will include both the fireside discussion and individual investor meetings, with a webcast link provided for virtual attendance.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) ha annunciato la sua partecipazione alla prossima Guggenheim SMID Cap Biotech Conference, in programma per il 5-6 febbraio 2025, a New York. Il CEO dell'azienda, Yuval Cohen, Ph.D., parteciperà a una discussione informale guidata da analisti e condurrà incontri individuali con gli investitori.
La presentazione è prevista per il 5 febbraio 2025 alle 14:30. Il formato includerà sia la discussione informale che incontri individuali con gli investitori, con un link alla trasmissione in streaming fornito per la partecipazione virtuale.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) ha anunciado su participación en la próxima Guggenheim SMID Cap Biotech Conference, que se llevará a cabo el 5 y 6 de febrero de 2025 en Nueva York. El CEO de la compañía, Yuval Cohen, Ph.D., participará en un diálogo informal dirigido por analistas y realizará reuniones individuales con inversionistas.
La presentación está programada para el 5 de febrero de 2025 a las 14:30. El formato incluirá tanto la discusión informal como las reuniones individuales con inversionistas, y se proporcionará un enlace para la asistencia virtual a través de webcast.
코르부스 제약홀딩스 (NASDAQ: CRBP)는 2025년 2월 5-6일 뉴욕에서 개최되는 구겐하임 SMID 캡 생명공학 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 유발 코헨, 박사는 애널리스트들이 주도하는 대화에 참여하고 투자자들과의 일대일 미팅을 진행할 예정입니다.
발표는 2025년 2월 5일 오후 2시 30분에 예정되어 있습니다. 형식은 대화와 개별 투자자 미팅을 포함하며, 가상 참석을 위한 웹캐스트 링크가 제공될 것입니다.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) a annoncé sa participation à la prochaine Guggenheim SMID Cap Biotech Conference, prévue les 5 et 6 février 2025 à New York. Le PDG de l'entreprise, Yuval Cohen, Ph.D., participera à une discussion en petit comité animée par des analystes et tiendra des réunions individuelles avec des investisseurs.
La présentation est prévue pour le 5 février 2025 à 14h30. Le format comprendra à la fois la discussion en petit comité et des réunions individuelles avec les investisseurs, avec un lien de webdiffusion prévu pour une participation virtuelle.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) hat seine Teilnahme an der bevorstehenden Guggenheim SMID Cap Biotech Conference bekannt gegeben, die am 5. und 6. Februar 2025 in New York stattfinden wird. Der CEO des Unternehmens, Yuval Cohen, Ph.D., wird an einer Gesprächsrunde teilnehmen, die von Analysten geleitet wird, und Einzelgespräche mit Investoren führen.
Die Präsentation ist für den 5. Februar 2025 um 14:30 Uhr angesetzt. Das Format umfasst sowohl die Gesprächsrunde als auch individuelle Investorengespräche, wobei ein Webcast-Link für die virtuelle Teilnahme bereitgestellt wird.
- None.
- None.
NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the Guggenheim SMID Cap Biotech Conference, to be held February 5-6, 2025 in New York, NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings.
Guggenheim Securities SMID Cap Biotech Conference
Format: Fireside Chat and one-on-one investor meetings
Presentation Date: February 5, 2025
Presentation Time: 2:30 PM
Webcast: Click here
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
When is Corbus Pharmaceuticals (CRBP) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
What type of presentation format will CRBP use at the Guggenheim Conference?
Where will the Guggenheim SMID Cap Biotech Conference 2025 featuring CRBP be held?
Who will represent CRBP at the Guggenheim SMID Cap Biotech Conference?
Will there be a webcast available for CRBP's presentation at the Guggenheim Conference?
